B7-H3 Antibody–Drug Conjugates in 2026: Emerging Clinical Evidence and Strategic Interest Across Oncology Drug Development

Biological and Therapeutic Rationale

B7 homolog 3 (B7-H3, also designated CD276) is a transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules. Its appeal as an antibody–drug conjugate (ADC) target rests on a compelling dual rationale: selective overexpression across a broad spectrum of solid tumors combined with multifaceted roles in both tumor-intrinsic malignancy and immune evasion 1.

At the protein level, B7-H3 is expressed at low levels in most normal tissues despite widespread mRNA distribution, while being markedly elevated in prostate, pancreatic, breast, colorectal, ovarian, lung, esophageal, and nasopharyngeal cancers, among others. In extensive-stage small cell lung cancer (ES-SCLC) specifically, B7-H3 is expressed across all molecular subtypes, with approximately 65% of tumors showing moderate-to-high immunohistochemical staining; elevated expression correlates with larger tumor size and significantly shorter overall survival 7. This differential protein expression between tumor and normal tissue underpins the therapeutic selectivity rationale for cytotoxic payload delivery 12.

Within the tumor microenvironment (TME), B7-H3 functions as a co-inhibitory checkpoint: it suppresses CD8+ and CD4+ T-cell responses, promotes regulatory T-cell (Treg) accumulation, drives tumor-associated macrophages toward the pro-tumor M2 phenotype, and inhibits natural killer (NK) cell activation, collectively establishing an immunosuppressive "cold" TME that resists conventional checkpoint inhibitor monotherapy 12. Beyond immunomodulation, B7-H3 also promotes tumor proliferation, migration, invasion, epithelial-to-mesenchymal transition, angiogenesis, and chemotherapy resistance 1. Preclinical studies have further demonstrated that B7-H3 is overexpressed on both cancer cells and tumor-infiltrating blood vessels, suggesting the possibility of dual-compartment targeting that simultaneously addresses cancer cells and tumor vasculature 4. These converging lines of biological evidence make B7-H3 an unusually attractive ADC target across histologies.

Emerging Clinical Evidence

The B7-H3 ADC clinical landscape as of mid-2026 is characterized by multiple agents in early-to-pivotal-phase development, with several compounds demonstrating meaningful activity across diverse solid tumor types 35.

Ifinatamab deruxtecan (I-DXd; DS-7300/MK-2400), developed by Daiichi Sankyo in global collaboration with Merck, remains the most clinically advanced B7-H3 ADC. It comprises a humanized anti-B7-H3 IgG1 monoclonal antibody conjugated via a tetrapeptide-based cleavable linker to a topoisomerase I inhibitor payload (DXd, an exatecan derivative), with a drug-to-antibody ratio (DAR) of approximately 4 7. In the IDeate-Lung01 Phase 2 trial enrolling 187 patients with ES-SCLC who had received prior platinum-based chemotherapy, I-DXd at 12 mg/kg every three weeks achieved a confirmed objective response rate (ORR) of 48.2%, a disease control rate (DCR) of 87.6%, median progression-free survival (PFS) of 4.9 months, and median overall survival (OS) of 10.3 months; the second-line subgroup (n=32) demonstrated an ORR of 56.3% 7. Critically, in April 2026, the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the Biologics License Application (BLA) for I-DXd in ES-SCLC, with a Prescription Drug User Fee Act (PDUFA) action date of October 10, 2026; the application is being reviewed under Real-Time Oncology Review (RTOR) and Project Orbis 7. I-DXd had previously received FDA Breakthrough Therapy Designation in August 2025 for this indication, as well as Orphan Drug Designation from the FDA, European Commission, Japan Ministry of Health, Labour and Welfare, and Taiwan FDA for SCLC, and an additional FDA Orphan Drug Designation for esophageal cancer 7. Three Phase 3 registrational trials are ongoing: IDeate-Lung02 (SCLC), IDeate-Prostate01 (castration-resistant prostate cancer, CRPC), and IDeate-Esophageal01 (esophageal squamous cell carcinoma) 7.

Tambotatug pelitecan (YL201), developed by MediLink Therapeutics (Suzhou) and leveraging the proprietary TMALIN® (Tumor Microenvironment Activable LINker) platform, has delivered the first positive Phase 3 result for any B7-H3 ADC worldwide. In May 2026, the Phase 3 TAISHAN-301 registrational trial in recurrent or metastatic nasopharyngeal carcinoma (NPC) met its pre-specified primary endpoint of confirmed ORR (cORR) as assessed by blinded independent central review (BICR), demonstrating statistically significant improvement versus chemotherapy; the co-primary endpoint of overall survival was not yet mature 10. In the preceding Phase 1b study across 287 evaluable patients with multiple advanced solid tumors, YL201 showed an overall ORR of 40.8%, DCR of 83.6%, and median PFS of 5.9 months; ES-SCLC cohort ORR reached 63.9% with a median PFS of 6.3 months; NPC ORR was 48.6%; and pulmonary lymphoepithelioma-like carcinoma (LELC) ORR was 54.2% 57. Safety was notably manageable with treatment-related ILD in only 1.3% of patients and infusion-related reactions in 0.3% 5. These data, published in Nature Medicine in March 2025, catalyzed the initiation of Phase 3 trials in ES-SCLC and NPC, and an FDA Breakthrough Therapy Designation for SCLC was granted in June 2025 10.

HS-20093 (risvutatug rezetecan; GSK5764227), developed by Hansoh Pharmaceutical and licensed globally to GSK outside mainland China/Hong Kong/Macau/Taiwan, has received three FDA Breakthrough Therapy Designations — for ES-SCLC, osteosarcoma, and locally advanced or metastatic non-squamous NSCLC without driver mutations — as well as EMA Priority Medicines (PRIME) Designation and Orphan Drug Designation for pulmonary neuroendocrine carcinoma 37. In the ARTEMIS-001 Phase 1 trial, HS-20093 at 8.0 mg/kg and 10.0 mg/kg in ES-SCLC achieved ORRs of 61.3% and 50.0%, respectively, with median PFS of 5.9 and 7.3 months; in patients receiving prior immunotherapy and platinum but no prior topoisomerase I (TOP1i) inhibitor, ORRs reached 75.0% and 66.7% 5. GSK initiated a global Phase 3 trial in August 2025 7.

DB-1311/BNT324, co-developed by Duality Biologics and BioNTech, demonstrated in a Phase 1/2a trial enrolling 277 patients an unconfirmed ORR (uORR) of 32.4% overall and 56.2% in 73 SCLC patients (70.4% at 9 mg/kg in immunotherapy-pretreated, TOP1i-naïve SCLC patients); in 32 evaluable metastatic CRPC (mCRPC) patients, uORR was 28.0% with a median radiographic PFS of 7.2 months 57. In March 2025, BioNTech initiated the first clinical evaluation of a B7-H3 ADC combined with a PD-L1/VEGF-A bispecific antibody (BNT327/PM8002) in advanced SCLC and NSCLC, representing a pioneering combination approach 7.

MacroGenics' vobramitamab duocarmazine (vobra duo), which used a duocarmycin DNA-alkylating payload, was evaluated in the TAMARACK Phase 2 trial in mCRPC. Updated data from the February 2025 cutoff showed mature median radiographic PFS of 9.5 months (2.0 mg/kg) and 10.0 months (2.7 mg/kg); however, following an internal resource and portfolio review, MacroGenics decided not to pursue further internal development of vobra duo in March 2025, while affirming continued confidence in the B7-H3 target and pivoting toward MGC026 — a next-generation anti-B7-H3 ADC sharing the same antibody variable domain but incorporating a glycan-linked TOP1i payload developed in collaboration with Synaffix — currently in Phase 1 dose escalation 9.

Across programs, several cross-cutting patterns merit attention: meaningful activity has been observed in SCLC across multiple agents; intracranial responses have been reported with several candidates including YL201 and DB-1311, relevant given the high CNS metastasis burden in SCLC; B7-H3 expression level by immunohistochemistry has not consistently predicted response across trials, challenging straightforward biomarker-driven enrollment; and hematologic toxicities (neutropenia, anemia, thrombocytopenia) represent a class-wide safety concern, with interstitial lung disease (ILD)/pneumonitis an adverse event of special interest particularly for I-DXd (12.4% any-grade in IDeate-Lung01) 357.

Comparative Product Landscape

The table below summarizes leading B7-H3 ADC programs as of June 2026.

Strategic Interest and Competitive Dynamics

The B7-H3 ADC field has attracted substantial pharmaceutical investment, with multiple high-value partnerships emerging between 2023 and 2026. The Daiichi Sankyo–Merck global collaboration (October 2023, expanded August 2024) represents the most comprehensive arrangement, covering multiple DXd ADC assets with I-DXd as the lead 7. GSK's December 2023 exclusive license of HS-20093 from Hansoh — involving $185 million upfront and up to $1.525 billion in success-based milestones — signals confidence in the B7-H3 target from a major Western pharma perspective 8. Most recently, Roche's exclusive global licensing agreement with MediLink for YL201 (January 2026) validates both the TMALIN® linker platform and the B7-H3 target class from an independent major pharma perspective 10.

The competitive density reflects a broader strategic recognition that B7-H3 may enable tumor-agnostic or multi-indication development pathways, particularly given its expression breadth. A notable geographic dimension has emerged: multiple China-based innovators (Hansoh, Medilink, Duality Biologics, Mabwell, Bio-Thera, Qilu/Minghui, InnoCare) are advancing B7-H3 ADCs rapidly domestically before expanding internationally, whereas global players pursue multinational Phase 3 programs concurrently 6. Convergence on topoisomerase I inhibitor payloads is apparent across most programs — I-DXd, YL201, HS-20093, DB-1311, MHB088C, MGC026 all employ or appear to employ TOP1i payloads — with MacroGenics' pivot away from the duocarmycin payload in vobra duo to a TOP1i strategy in MGC026 further reinforcing this trend 9. The outlier approach represented by ABBV-155's Bcl-XL inhibitor payload yielded limited monotherapy activity, underscoring the importance of payload selection 3.

Key Unresolved Questions and Future Directions

Despite the impressive early clinical signals, several fundamental questions will determine the ultimate clinical and commercial positioning of B7-H3 ADCs.

Biomarker strategy and patient selection represent perhaps the most pressing challenge. Across multiple programs — most explicitly I-DXd and YL201 — no consistent correlation between tumor B7-H3 expression level and clinical response has been established, challenging the assumption that target abundance linearly predicts efficacy 357. Whether baseline expression thresholds, spatial distribution, soluble B7-H3 levels, or co-occurring genomic alterations can enrich for responders remains an open research priority for pivotal trials.

Interstitial lung disease and on-target toxicity require vigilant monitoring and mechanistic investigation. ILD/pneumonitis incidence varies substantially across programs — 12.4% with I-DXd in IDeate-Lung01 (grade ≥3: 4.4%) versus 1.3% with YL201 — and whether this reflects differences in linker/payload properties, dosing schedules, or patient population composition is unknown 57. Understanding whether B7-H3 expression in lung tissue represents an on-target driver of ILD is mechanistically unresolved 3.

Resistance mechanisms and durability remain incompletely characterized. Median PFS values across programs typically range from approximately 5 to 7 months in SCLC cohorts, with durable responses observed in a minority of patients. Prospective molecular studies embedded in pivotal trials will be needed to identify primary and acquired resistance drivers and to design rational sequencing and combination strategies.

Combination approaches are in early clinical exploration. The DB-1311 + BNT327/PM8002 trial launched in March 2025 represents the first attempt to evaluate synergy between a B7-H3 ADC and a PD-L1/VEGF dual-targeting bispecific antibody 7. Given the immunosuppressive TME properties of B7-H3-expressing tumors, rational combination with immune checkpoint inhibitors, anti-angiogenic agents, or chemotherapy backbones may be required to overcome the immunologic resistance that limits single-agent immunotherapy in these histologies 12.

Conclusion

As of June 2026, B7-H3 ADCs represent one of the most clinically active frontiers in solid tumor oncology. Ifinatamab deruxtecan is under FDA Priority Review for ES-SCLC with a PDUFA date of October 2026 — potentially becoming the first approved B7-H3-directed therapy — while YL201's Phase 3 success in NPC marks the first positive pivotal trial result for this target class 710. Major pharmaceutical endorsements from Merck, GSK, and Roche further validate strategic confidence in B7-H3. The convergence on topoisomerase I inhibitor payloads, the emergence of intracranial activity signals, and the delivery of clinically meaningful ORRs in historically treatment-refractory SCLC collectively underscore the therapeutic potential of this class. However, registration-enabling evidence from randomized Phase 3 trials, biomarker-validated patient selection strategies, long-term safety characterization, and mechanistically informed combination regimens remain critical unmet needs that will define the clinical role of B7-H3 ADCs in the years ahead 356.